Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) EBIT (2016 - 2025)

Historic EBIT for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$14.3 million.

  • Northwest Biotherapeutics' EBIT rose 324.98% to -$14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.9 million, marking a year-over-year decrease of 278.38%. This contributed to the annual value of -$66.5 million for FY2024, which is 1981.7% down from last year.
  • As of Q3 2025, Northwest Biotherapeutics' EBIT stood at -$14.3 million, which was up 324.98% from -$14.8 million recorded in Q2 2025.
  • Northwest Biotherapeutics' 5-year EBIT high stood at -$10.0 million for Q3 2021, and its period low was -$21.1 million during Q2 2022.
  • Moreover, its 5-year median value for EBIT was -$14.8 million (2024), whereas its average is -$15.2 million.
  • Data for Northwest Biotherapeutics' EBIT shows a peak YoY increase of 7901.08% (in 2021) and a maximum YoY decrease of 14984.04% (in 2021) over the last 5 years.
  • Northwest Biotherapeutics' EBIT (Quarter) stood at -$10.7 million in 2021, then crashed by 70.27% to -$18.2 million in 2022, then rose by 16.7% to -$15.1 million in 2023, then decreased by 22.17% to -$18.5 million in 2024, then rose by 22.59% to -$14.3 million in 2025.
  • Its EBIT stands at -$14.3 million for Q3 2025, versus -$14.8 million for Q2 2025 and -$17.3 million for Q1 2025.